Skip to content
BiologicalX

Comparison

Methylene Blue vs Omega-3 (EPA/DHA)

Side-by-side of Methylene Blue and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Methylene Blue

  • FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
  • Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
  • Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
  • Causes harmless blue-green urine and sweat coloration; useful adherence marker
  • G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
  • Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Methylene Blue Omega-3 (EPA/DHA)
Category pharmaceutical supplement
Also known as Methylthioninium chloride, Provayblue, tetramethylthionine chloride fish oil, EPA, DHA, marine omega-3
Half-life (hr) 5.5 48
Typical dose (mg) 70 2000
Dosing frequency 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia 1 to 2 times daily with food
Routes oral, intravenous oral
Onset (hr) 1 4
Peak (hr) 1.5 12
Molecular weight 319.85 302.45
Molecular formula C16H18ClN3S C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status allowed allowed
DEA / Rx Not scheduled in the US Not scheduled
Pregnancy Contraindicated Recommended at 200 to 600 mg DHA/day for fetal development
CAS 61-73-4 10417-94-4
PubChem CID 6099 446284
Wikidata Q409021 Q207688

Safety profile

Methylene Blue

Common side effects

  • blue-green urine and sweat
  • skin and oral mucosa staining
  • GI upset
  • headache
  • dizziness

Contraindications

  • G6PD deficiency
  • pregnancy
  • concurrent serotonergic medication
  • severe renal impairment
  • infants under 6 months

Interactions

  • SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
  • MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
  • fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
  • dextromethorphan: serotonin syndrome risk(major)
  • St John's wort: serotonin syndrome risk(major)
  • lithium: additive serotonergic risk(major)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Methylene Blue is the right call when one of the conditionals below applies.

Edge case: If you want to avoid controlled substance, Omega-3 (EPA/DHA) is the more accessible choice.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Methylene Blue only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Methylene Blue and Omega-3 (EPA/DHA)?

Methylene Blue and Omega-3 (EPA/DHA) differ in category (pharmaceutical vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Methylene Blue or Omega-3 (EPA/DHA)?

Methylene Blue half-life is 5.5 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Methylene Blue with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper